We take no money from the companies we review: no ads, no affiliate links, no sponsorships. Our editorial independence

HomeTrials › NCT07668414

Obesity & weight · Phase 3 · Opening soon

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

NCT07668414 · Sponsor: Novo Nordisk A/S

What this trial means for you

This study is opening soon at 46 US sites. It's studying Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide) for overweight, obesity.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo, diagnosis required
What you'd takeZenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
Study length~2.1 years overall
Planned participants650
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.

Study sites by state

California

  • First Valley Medical Group, Lancaster
  • Desert Oasis Healthcare, Palm Springs
  • Western University of Health Sciences, Pomona
  • Artemis Insitute for Clin Res, San Diego

District of Columbia

  • Med Home Development Grp, Washington D.C.

Florida

  • Encore Medical Research LLC, Hollywood
  • NextPhase Research, Hollywood
  • Jacksonville Ctr Clin Res, Jacksonville
  • PharmaDev Clinical Research Institute LLC, Miami
  • South Broward Research LLC, Miramar
  • Essence MD Research, Naples
  • Florida Inst For Clin Res LLC, Orlando
  • Oviedo Medical Research, LLC, Oviedo
  • Palm Beach Research Center, West Palm Beach
  • Encore Medical Research of Weston, Weston

Georgia

  • Conquest Research, Atlanta
  • Eastside Bariatric and Gen Surg, Snellville

Illinois

  • Chicago Research Center, Inc, Chicago
  • Endeavor Health, Skokie

Indiana

  • Midwest Inst For Clin Res, Indianapolis

Louisiana

  • Southern Clin Research, Zachary

Missouri

  • Amicis Centers of Clinical Research, St Louis

New York

  • Ichor Research, Syracuse
  • Southgate Medical Group, LLP, West Seneca

North Carolina

  • University of North Carolina, Chapel Hill
  • PharmQuest Life Sciences LLC, Greensboro
  • Piedmont Healthcare/Research, Statesville

North Dakota

  • Lillestol Research LLC, Fargo

Pennsylvania

  • Geisinger Clinic, Danville

South Carolina

  • Medical University Of South Carolina, Charleston
  • Hillcrest Clinical Research, Simpsonville
  • Spartanburg Medical Research, Spartanburg

Texas

  • Amarillo Med Spec LLP, Amarillo
  • Texas Diabetes & Endocrinology, Austin
  • Pinnacle Clinical Research, Brownsville
  • Osvaldo A. Brusco MD, Corpus Christi
  • UT Southwestern Med Center, Dallas
  • Epic Medical Research, DeSoto
  • Houston Research Institute, Houston
  • The Endocrine Center, Houston
  • Sleep Therapy Research Center, San Antonio
  • Olympus Clinical Research, Sugar Land

Virginia

  • National Clin Res Inc., Richmond
  • Gastroent Consult of SW VA, Roanoke

Washington

  • Rainier Clin Res Ctr Inc, Renton
  • Seattle Clinical Research Center, Seattle

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently, so always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Keep researching on StudyBackedHealth